Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023 in Chicago, Illinois. The presentation will focus on the BRACELET-1 trial, which evaluates the use of pelareorep in combination with paclitaxel and avelumab for treating metastatic HR+/HER2- breast cancer. Dr. Matt Coffey, CEO, emphasized the significance of this recognition, stating it highlights the trial's importance to oncology stakeholders. The abstract, numbered 1012, will be published on the ASCO website on May 25, 2023. Oncolytics is advancing pelareorep through several clinical trials aimed at enhancing treatment outcomes for various cancers.
- Acceptance of abstract for oral presentation at ASCO highlights credibility.
- BRACELET-1 trial results may attract more investment and interest in pelareorep.
- Potential synergy of pelareorep with existing oncology treatments is promising.
- None.
Oral presentation on BRACELET-1 to take place on
"Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer," said Dr.
Details on the abstract and corresponding presentation are shown below.
Title: BRACELET-1 (PrE0113): Inducing an Inflammatory Phenotype in Metastatic HR+/HER2- Breast Cancer with the Oncolytic Reovirus Pelareorep in Combination with Paclitaxel and Avelumab
Presentation Type: Oral
Abstract Number: 1012
Session Type: Clinical Science Symposium
Session Title: The Dr.
Session Date and Time:
The abstract will be published on the ASCO Annual Meeting website at
About BRACELET-1
Additional information on the BRACELET-1 study can be found at https://clinicaltrials.gov/ct2/home and the identifier (NCT number) NCT04215146.
About
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; our plans to conduct clinical trials evaluating pelareorep in combination with checkpoint inhibitors and target therapies in solid and hematological malignancies; our plans to advance towards registration studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics +1-917-679-9282 |
View original content:SOURCE Oncolytics Biotech® Inc.
FAQ
What is the significance of the BRACELET-1 trial for Oncolytics Biotech?
When will the oral presentation on the BRACELET-1 trial occur?
Where can I find more information about Oncolytics Biotech's clinical trials?
What are the main components of the BRACELET-1 trial?
What abstract number is assigned to the BRACELET-1 trial presentation?
